Skip to main content
. 2018 Sep 17;10(9):1315. doi: 10.3390/nu10091315

Table 8.

Adjusted changes in metabolic, renal and biomarker parameters between placebo and Tocovid group.

Analytes Placebo Group Tocovid Group Mean Difference p-Value
HbA1c (%) 8.61 ± 0.17 8.45 ± 0.17 −0.16 ± 0.24 0.518
SBP (mmHg) 137.09 ± 2.81 130.48 ± 2.88 −6.62 ± 4.03 0.108
DBP (mmHg) 77.61 ± 1.78 77.91 ± 1.82 0.297 ± 2.57 0.909
Weight (kg) 78.22 ± 0.84 79.47 ± 0.86 1.24 ± 1.20 0.308
Renal parameters:
UACR (mg/mmol) 66.93 ± 8.93 85.43 ± 9.14 18.45 ± 12.97 0.161
Sr Creatinine (μmol/L) 131.04 ± 2.92 119.76 ± 2.92 −11.28 ± 4.31 * 0.014
eGFR (mL/min/1.73 m²) 74.89 ± 11.51 63.57 ± 11.77 −11.31 ± 16.51 0.497
Serum biomarkers:
AGE (µg/mL) 83.66 ± 27.20 89.82 ± 27.20 6.16 ± 38.50 0.874
sRAGE (pg/mL) 1088.32 ± 111.65 1246.36 ± 114.16 158.05 ± 159.77 0.328
Nε-CML (ng/mL) 2.56 ± 0.48 2.59 ± 0.49 0.28 ± 0.69 0.967
Cystatin C (ng/mL) 2172.45 ± 181.56 2031.99 ± 185.64 −140.46 ± 259.66 0.591
Safety tests:
Urea (mmol/L) 7.33 ± 0.37 7.26 ± 0.38 −0.07 ± 0.54 0.896
Total chol (mmol/L) 4.52 ± 0.12 4.67 ± 0.12 0.15 ± 0.17 0.384
HDL (mmol/L) 1.17 ± 0.03 1.18 ± 0.03 0.01 ± 0.04 0.772
AST (IU/L) 21.21 ± 0.91 19.41 ± 0.93 −1.80 ± 1.35 0.190
ALT (IU/L) 26.45 ± 1.67 22.17 ± 1.71 −4.28 ± 2.46 0.089

All values are presented as means ± standard errors of the mean. Data adjusted for baseline values and age. Data adjusted for baseline value, age, weight, HbA1c, SBP, DBP, age, weight, AGE, CML, sRAGE, and Cystatin C. * Significant at p < 0.05. HbA1c: Hemoglobin A1c, SBP: Systolic blood pressure, DBP: Diastolic blood pressure, BMI: Body mass index, DM: Diabetes mellitus, UACR: Urine albumin to creatinine ratio, eGFR: estimated Glomerular Filtration Rate, AGE: Advanced Glycation Endproduct, sRAGE: soluble Receptor for AGE, Nε-CML: Nε-Carboxymethyllysine, Total chol: Total cholesterol, HDL: High density lipoprotein, AST: Aspartate Aminotransferase, ALT: Alanine aminotransferase.